1st Swiss Industrial Chemistry Symposium, SICS 2016
| Start Date | 28.10.2016 - 08:30 |
| Event End | 28.10.2016 - 18:00 |
| Location | Universität Basel, Organische Chemie |
The symposium offers a unique platform for industrial scientists, working in research and process research, to present their latest results, to interact with each other and to network with professors, PhD students and other scientific staff of Swiss universities. An extended poster session with presentations from industry (20%) and academy (80%) will stimulate the interaction.
Confirmed Speakers:
- Dr. Andreas Marzinzik, Novartis Pharma AG, «Towards the goal of curing CML: discovery of ABL001 a novel allosteric inhibitor of BCR-ABL preventing disease relapse by dual targeting»
- Dr. Kurt Püntener, F. Hoffmann-La Roche AG, «With asymmetric hydrogenation towards scalable, stereoselective syntheses of Aleglitazar and Bitopertin»
- Dr. Ulla Létinois, DSM Nutritional Products AG, «Bio-based aromatic building blocks for vitamin E manufacture»
- Dr. Cheng-yi Chen, Janssen R&D, Cilag AG, «A Synthesis of 1H-Indazoles via a Cu(OAc)2-catalyzed N-N Bond Formation»
- Dr. Kai-Uwe Schöning, BASF Schweiz AG, «Hindered amine polymer stabilizers – new discoveries in an established research area»
- Dr. Alec Birkbeck, Firmenich SA, «From Leopold Ruzicka in 1935 until now: the story of (Z)-β-Santalol at Firmenich, towards an industrial synthesis»
- Dr. Corinna Nimphius, Clariant International Ltd, «Glucamides – a new platform of sugar-based surfactants»
- Dr. Wolfgang Haap, F. Hoffmann-La Roche AG, «Discovery of the cathepsin S inhibitor RG7625 for the treatment of autoimmune diseases»
- Dr. Myriem El Qacemi, Syngenta Crop Protection AG, «Enantioselective synthesis of insecticidal isothiazolines»
- Dr. Fabrice Gallou, Novartis Pharma AG, «Alternative solvents: from a compliance-driven activity to a trigger for innovation»
- Dr. Johannes Schranck, Solvias AG, «Catalysis @ Solvias – from science to business»
- Dr. Christian Lothschütz, Siegfried AG, Zofingen, «What can academia learn from industry?»
- Dr. Stefan Abele, Actelion Pharmaceuticals Ltd., «Pilot plant production of a P2Y12-antagonist containing (R)-3-Phosphonoalanine»
- Dr. Christoph Taeschler, Lonza AG, «Process development aspects of alkylnitrites»
- Dr. Rolf Schaller, Dottikon Exclusive Synthesis AG, «Advanced process development into future»
Contact:
Co-Chairman and Program Coordinator
Dr. Remo Gamboni
F. Hoffmann-La Roche AG
4070 Basel
+41 61 688 24 58
Organizing Commitee:
Dr. Remo Gamboni, F. Hoffmann-La Roche AG, Chair
Prof. Olivier Baudoin, University of Basel
Dr. Jérôme Cassayre, Syngenta Crop Protection AG
Dr. Alain De Mesmaeker, Syngenta Crop Protection AG
Dr. Fabrice Gallou, Novartis Pharma AG
Dr. Thomas Heinz, Novartis Pharma AG
Dr. Guido Koch, Novartis Pharma AG
Dr. Andrew W. Thomas, F. Hoffmann-La Roche AG
David Spichiger, Swiss Chemical Society